The Protocol is targeted at the national public health reference laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
This report describes many of the aspects that should be taken into account. It systematically covers the entire process from sample provision and sequencing to data analysis and collaboration with other organisations.
This protocol for harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter from human isolates aims to increase the quality and comparability of antimicrobial resistance data collected at the EU level from different Member States. It is primarily targeted to the National Public Health Reference Laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
In May 2012 a collection of five strains of Haemophilus spp was sent to 28 participating reference laboratories in the IBD-labnet surveillance network for quality assurance testing. The laboratories were asked to characterise the five strains by performing standard laboratory protocols for the methods usually used by the laboratory for: species identification, biotyping and serotyping by serological methods and/or PCR.
The results of this EQA are published in the this report.
In June 2009, ECDC convened a technical expert consultation that focused on tuberculosis, new emerging airborne diseases (e.g. SARS) and meningococcal infections. This consultation was the second of a two-part process intended to assist national authorities in the EU Member States in the assessment of risks associated with the transmission of various infectious agents on board airplanes.
In the closed cabin environment of modern airplanes, passengers are frequently exposed to various infectious diseases. This report looks at 12 infectious diseases and, by systematically evaluating literature on on-board transmission, attempts to assess the risk of infection via air circulation in airplanes.
These guidelines are complemented by operational guidelines in relation to tuberculosis, new emerging airborne diseases (e.g. SARS) and meningococcal infections.